SHEET 5 OF 8

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY, DOCKET NO. TRIPEP.056A	APPLICATION NO. 10/773,628
	DISCLOSURE STATEMENT Y APPLICANT	APPLICANT Matti Sällberg	
(USE SEVERAL	. SHEETS IF NECESSARY)	FILING DATE February 5, 2004	GROUP Unassigned

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)			
/L.H./	98.	Felding-Habermann et al., "Role of ß3 Integrins in Melanoma Cell Adhesion to Activated Platelets under Flow," J. Biol. Chem., 271(10):5892-5900 (1996).		
/L.H./	99.	Flock, "Extracellular-Matrix-Binding Proteins as Targets for the Prevention of Staphylococcus Aureus Infections," (1999) Molecular Medicine Today, Vol. 5 pp 532-537.		
/L.H./	100.	Ganem, "Hepadnaviridae and Their Replication," Fields Virology, Third Ed., Ch. 85, pp. 2703-2705, 1996.		
/L.H./	101.	GenCore sequence alignment of SEQ ID NO: 16 with the L-chain variable region of plasminogen activator antibody of JP61172900-A, Ashi Chemical Ind. KK. 4/8/1986, ID NO: p. 61027.		
	102.	GEYCOPROTEINS, http://www.cs.stedwards.edu/chem/Chemistry/CHEMAS/CHEMAS/Glycoproteins/Glycopro.		
<del></del>	<del>-103.</del>	CLYCOPROTEINS, http://www.users.ron.com/ikimball.ma.ultmet/BiologyPages/G/Glycoproteins.html.		
/L.H./	104.	Grabowska et al., "Identification of type-specific domains within glycoprotein G of herpes simplex virus 2 (HSV-2) recognized by the majority of patients infected with HSV-2, but not by those infected with HSV-1," <i>Journal of General Virology</i> , 80(7):1789-1798 (1999).		
/L.H./	105.	Greenspan et al., "Defining epitopes: It's not as easy at it seems," Nature Biotechnology, Vol. 17, pp. 936-937, October 1999.		
/L.H./	106.	Haseltine "Replication and Pathogenesis of the AIDS Virus," Journal of Acquired Immune Deficiency Syndromes 1(3):217-240 and 231-236, (1988).		
/L.H./	107.	Henschen A. et al., "Preliminary Note on the Completion of the β-Chain Sequence", (1997) Z. Physiol. Chem., 358:1643-1646.		
. /L.H./	108.	Holliger et al., "'Diabodies': Small Bivalent and Bispecific Antibody Fragments," Proc Natl. Acad. Sci. USA, 90:6444-6448, July 1993.		
/L.H./	109.	Huse et al., "Generation of a large combinatorial library of the immunologlobulin repertoire in Phage Lambda," Science, 246:1275-1281 (1989).		
/L.H./	110.	Jin et al., "Expression, Isolation, and Characterization of the Hepatitis C Virus ATPase/RNA Helicase," Archives of Biochemistry and Biophysics, 323:47-53 (1995).		
/L.H./		Katada et al., "A Novel Peptide Motif for Platelet Fibrinogen Receptor Recognition," J. Biol. Chem., 272(12):7720-7726 (1997).		
/L.H./	112.	Korba and Gerin, "Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication," <i>Antiviral Res.</i> , 19(1):55-70 (1992), ABSTRACT ONLY.		
/L.H./	113.	Korba and Milman, "A cell culture assay for compounds which inhibit hepatitis B virus replication," Antiviral. Res. 15(3):217-228 (1991).		
/L.H./	114.	Kreitman et al., "Immunotoxins for targeted cancer therapy," Advanced Drug Delivery Reviews, 31:53-88 (1998).		
	115.	Lazdina et et., Journal of Virology, 75(14):6367-6374, July 2001.		
/L.H./	116.	Leanna & Hannink, "The reverse two-hybrid system: a genetic scheme for selection against specific protein/protein interactions," Nucl. Acid. Res., 24(17):3341-3347 (1996).		
/L.H./	117.	Lee et al., "Predominant Etiologic Association of Hepatitis C Virus with Hepatocellular Carcinoma Compared with Hepatitis B Virus in Elderly Patients in a Hepatitis B-Endemic Area," Cancer, 72:2564-2567 (1993).		
/L.H./	118.	118. Levi et al., "A Complementarity-Determining Region Synthetic Peptide Acts as a Miniantibody and Neutralizes Human Immunodificiency Virus Type 1 in vitro," Proc. Natl. Acad. Sci. USA, 90: 4374-4378, May 1993.		
/L.H./	119.	Lew et al., "Site-directed immune responses in DNA vaccines encoding ligand-antigen fusions," Vaccine, England, Vol. 18, No. 16, pp. 1681-1685 (2000).		

EXAMINER	/Louise Humphrey/	DATE CONSIDERED	10/02/2007
*EXAMINER: IN IN CONFORMAT	IITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION I NCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WIT	S IN CONFORMANCE WITH	MPEP 608; DRAW LINE THROUGH CITATION IF NOT TO APPLICANT.

10/02/2007

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT		APPLICATION NO. 10773,628
BY APPLICANT	APPLICANT Matti Sällberg	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE	GROUP

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)		
/L.H./	120.	Li et al., "Adenovirus-mediated expression of pig α(1,3) galactosyltransferase reconstructs Gal α(1, 3) Gal epitope on the surface of human tumor cells," <i>Cell Research</i> , 11(2):116-124 (2001), <a href="http://www.cell-research.com/20012/01-2-xl.html">http://www.cell-research.com/20012/01-2-xl.html</a> .	
/L.H./	121.	Lottspeich F. et al., "Preliminary Note on the Completion of the γ-Chain Sequence," (1977) Z. Physiol. Chem., 358:935-938.	
/L.H./	122.	Lowman HB, "Bacteriophage display and discovery of peptide leads for drug development," Annu. Rev. Biophys. Biomol. Struct., 26:401-424 (1997).	
/L.H./	123.	Machida A, et al., "Antigenic sites on the arginine-rich carboxyl-terminal domain of the capsid protein of hepatitis B virus distinct from hepatitis B core or e antigen," Mol. Immunol., 26(4):431-421 (1989).	
/L.H./	124.	McDevvit et al., "Characterization of the interaction between the Staphylococcus aureus clumping factor (ClfA) and fibrinogen," Eur. J. Biochem., 247(1):416-424 (1997).	
/L.H./	125.	McDevitt et al., "Identification of the ligand-binding domain of the surface-located fibrinogen receptor (clumping factor) of Staphylococcus aureaus," <i>Molecular Microbiology</i> , 16(5):895-907 (1995).	
/L.H./	126.	Milich et al., "Role of B cells in antigen presentation of the hepatitis B core," <i>Proc. Natl. Acad. Sci. USA</i> , 94:14648-14653, 1997.	
/L.H./	127.	Milich et al., "The humoral immune response in acute and chronic hepatitis B virus infection," Springer Semin. Immunopathol., 17:149-166 (1995).	
/L.H./	128.	Milich et al., "The Nucleocapsid of Hepatitis B Virus is Both a T-Cell-Independent and a T-Cell-Dependent Antigen," Science, 234:1398-1401 (1986).	
/L.H./	129.	Mollick et al., "Localization of a Site on Bacterial Superantigens That Determines T Cell Receptor 3 Chain Specificity," J. Exp. Med., 177:283-293 (1993).	
/L.H./	130.	Morrison et al., "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," <i>Proc. Natl. Acad. Sci. USA</i> , 81(21):6851-6855 (1984).	
/L.H./	131.	Neuberger et al., "Recombinant antibodies possessing novel effector functions," Nature, 312:604-608 (1984).	
/L.H./	132.	Ogg et al., "Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class l/peptide complexes," <i>British Journal of Cancer</i> , 82(5):1058-1062 (2002).	
/L.H./	133.	Owens et al., "Mapping the Collagen-Binding Site of Human Fibronectin by Expression in Escherichia Coli," Embo Journal, IRL Press, Eynsham, GB, Vol. 5, No. 11, pp. 2825-2830 (1986).	
/L.H./	134.	Pel et al., "Functional Studies of a Fibrinogen Binding Protein from Staphylococcus Epidermidis," (1999) Infection and Immunity, p 4525-4530.	
/L.H./	135.	Prange et al., "Chaperones involved in hepatitis B virus morphogenesis," Biol. Chem., Mar. 1999, 380(3):305-314.	
/L.H./		Ramberg, "The Nutrition Science Site: Glyconutritionals," http://glycoscience.com/glycoscience/document viewer.wm?&ID=719 (2000).	
	<del>- 137.</del>	Rendell et al., "High throughput Chemistry teward Complex Carbohydrates and Carbohydrate like Compounds", http://www.bentham.org/sample-issues/schts5-2/anya/anya-me.htm.	
/L.H./	138.	Roivanen et al., "Antigenic regions of poliovirus type 3/Sabin capsid proteins recognized by human sera in the peptide scanning technique," <i>Virology</i> , 180:99-107 (1991).	
/L.H./	139.	Rudd et al., "Glycosylation and the Immune System," Science, 291:2370-2376 (2001) http://sciencemag.org.	
/L.H./	140.	Rudd et al., "The role of glycosylation in the immune system and inflammation," Research Groups-Dept. of Biochemistry, Oxford, http://www.bioch.ox.ac.uk/rgroups/rgroupsnew.asp?Group_ID=40.	

EXAMINER	/Louise Humphrey/	DATE CONSIDERED 10/02/2007	
*EXAMINER: INI	ITIAL IF CITATION CONSIDERED, WHETHE ICE AND NOT CONSIDERED, INCLUDE CO	OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NO CONTROL OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	от

ĺ	FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. TRIPEP.058A	APPLICATION NO. 10/773,628
		DISCLOSURE STATEMENT Y APPLICANT	APPLICANT Matti Sällberg	1
	(USE SEVERAL	SHEETS IF NECESSARY)	FILING DATE February 5, 2004	GROUP Unassigned

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)		
/L.H./	141. Rüther and Müller-Hill, "Easy identification of cDNA clones," EMBO Journal, 2(10):1791-1794 (1983).		
/L.H./	Salfeld J, et al., "Antigenic determinants and functional domains in core antigen and e antigen from hepati virus," <i>Journal of Virology</i> , 63(2):798-808 (1989).		
/L.H./	Sällberg et al., "Characterization of a linear binding site for a monoclonal antibody to hepatitis B core antig Med. Virol., 33(4):248-252 (1991).	gen," <i>J</i> .	
/L.H./	Sällberg et al., "Human and murine B-cells recognize the HBeAg/beta (or HBe2) epitope as a linear determinant," Mol. Immunol., 28(7):719-726 (1991).		
/L.H./	145. Sällberg et al., "Immunochemical structure of the carboxy-terminal part of hepatitis B e antigen: identification internal and surface-exposed sequences," <i>Journal of General Virology</i> , 74: 1335-1340, 1993.	ion of	
	146. Sällberg et et., Poptides: Chemistry and Biology, pp. 715-710, 1993.		
/L.H./	147. Sällberg et al., "Rapid 'tea-bag' peptide synthesis using 9-fluorenylmethoxcarbonyl (Fmoc) protected amin acids applied for antigenic mapping of viral proteins," <i>Immunology Letters</i> , 30:59-68, 1991.		
/L.H./	148. Sällberg et al., "Synthetic peptides as mini antibodies," <b>Peptides: Chemistry and Biology</b> , eds. Hodges, J. Rivier, ESCOM, Leiden, pp. 715-718 (1993).	R. and	
/L.H./	Sällberg et al., "The Antigen/Antibody Specificity Exchanger: A New Peptide Based Tool for Re-directing Antibodies of Other Specificities to Recognize the V3 Domain of HIV-1 GP120," <i>Biochemical and Biophysi Research Communications</i> , 205:1386-1390 (1994).		
/L.H./	Sällberg, M. "Ligand/Receptor Specificity Exchangers that Redirect Antibodies to Receptors on a Pathoge U.S. Patent Application Serial Number 09/664,945, Filed September 19, 2000.		
/L.H./	Sallberg, M., "Ligand/Receptor Specificity Exchangers that Redirect Antibodies to Receptors on a Pathoge U.S. Patent Application Serial Number 09/664,025, Filed September 19, 2000.	en,"	
/L.H./	Sällberg, M. "Synthetic Peptides That Bind to the Hepatitis B Virus Core and E Antigens," U.S. Patent Application Serial Number 10/153,271, Filed May 21, 2002.		
/L.H./	<ol> <li>Saragovi, et al., "Design and Synthesis of a Mimetic from an Antibody Complementarity-Determining Regions Science, 253: 792-795, August 16, 1991.</li> </ol>	ion"	
/L.H./	154. Schödel, et al., "Structure of Hepatitis B Virus Core and e-Antigen," The Journal of Biological Chemistry, 268:1332-1337, 1993.		
/L.H./	155. Sears et al., "Toward Automated Synthesis of Oligosaccharides and Glycoproteins," Science, Vol. 291, pp 2350, 03/23/01, http://www.sciencemag.org.	. 2344-	
/L.H./	156. Sequence alignment of Genseq sequence alignment of instant SEQ ID NO: 28 with the anithuman parathy hormone-related protein of JP04228089-A, Kaneka Corp., August 18, 1992, ID NO: AR27008.	•	
/L.H./	157. Sequence alignment of Genseq sequence alignment of instant SEQ ID NO: 29 with anti-DNA antibody 7b3 heavy chain variable region of WO 96/36361-A1, University of Michigan, August 12, 1997, ID NO: AAW04	1593.	
/L.H./	158. Sequence alignment of Genseq sequence alignment of Instant SEQ ID NO: 33 with anti-proenkephalin and PE-19 of WO 9606863-A1, University of Dundee, October 9, 1996, ID NO: AAR91370.	tibody	
/L.H./	159. Signals Magazine: Buzz – Glycosylation Matters 06/06/02, http://www.signalsmag.com/signalsmag.nsf/0/A08BFCD79126B34F88256BCE0011B41A.		
	100. Skrivelis et al., Seend. J. Immunel., 37:637 643, 1903.		
	181. Steinberge et al., Proceedings of the Latvian Academy of Sciences, Section B, 50(2):74-77, 1990.		
/L.H./	Takahashi et al., "Acute hepatitis in rates expressing human hepatitis B virus transgenes," Proc. Natl. Acad USA, 92:1470-1474 (1995).	id. Sci.	
/L.H./	163. Takeda et al., "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," <i>Nature</i> , 314:452-454 (1985).	d	

EXAMINER	/Louise Humphrey/	DATE CONSIDERED	10/02/2007
*EXAMINER: II	NITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION NOT CONSIDERED, INCLUDE COPY OF THIS FORM W	N IS IN CONFORMANCE WITH	MPEP 609; DRAW LINE THROUGH CITATION IF NOT

	 ~ .	2 ^	

_					01100101
	FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY, DOCKET NO. TRIPEP.056A	APPLICATION NO. 10/773,628	
		DISCLOSURE STATEMENT Y APPLICANT	APPLICANT	 	
l			Matti Sällberg		
	(USE SEVERA	L SHEETS IF NECESSARY)	FILING DATE February 5, 2004	GROUP Unassigned	

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)		
/L.H./	164.	Taub R. et al., "A monoclonal antibody against the platelet fibrinogen receptor contains a sequence that mimics a receptor recognition domain in fibrinogen," <i>J. Biol. Chem.</i> , 264(1):259-265 (1989).	
	165	The Columbia Encyclopedia, Sixth Edition, Copyright 2002, Columbia University Press,	
		http://www.bartleby.com/65/gl/glycopro.html-	
. /L.H./	166.	Tramontano et al., "The Making of the Minibody: An Engineered Beta-Protein for the Display of Conformationally Constrained Peptides," <i>J. of Molecular Recognition</i> , 7(1): 9-24 (1994).	
/L.H./	167.	Watt K.W.K. et al., "Amino Acid Sequence Studies on the α Chain of Human Fibrinogen Overlapping Sequences Providing the Complete Sequence," (1979) <i>Biochemistry</i> , Vol. 18, pp 5410-5416.	
	168.	Watt K.W.K. et al., "Amino Acid Sequence of the β Shain of Human Fibrinogen," Biochemistry, Vol. 49, pp 69 76.	
/L.H./	169.	Williams et al., "Design of bioactive peptides based on antibody hypervariable region structures. Development of conformationally constrained and dimeric peptides with enhanced affinity," <i>J. Biol. Chem.</i> , 266(8):5182-5190 (1991).	
/L.H./	170.	Williams et al., "Development of biologically active peptides based on antibody structure," <i>Proc. Natl. Acad. Sci. USA</i> , 86(14):5537-5541 (1989).	
/L.H./	171.	Winter and Milstein, "Man-made antibodies," Nature, 349(6307):293-299 (1991).	
/L.H./	172.	P.R. Wood, HF. Seow, "T cell cytokines and disease prevention," Veterinary Immunology and Immunopathology, 54(1996) pp. 33-44.	
/L.H./	173.	Zanetti M., "Antigenized Antibodies" Nature, 355: 476-477, January 30, 1992.	
/L.H./	174.	Zhang et.al., "Characterization of a monoclonal antibody and its single-chain antibody fragment recognizing the nucleoside triphosphatase/helicase domain of the hepatitis C virus nonstructural 3 protein," Clin. Diagn. Lab. Immunol.; 7(1):58-63 (2000).	
/L.H./	175.	175. Zhang et al., "Molecular basis for antibody cros-reactivity between the hepatitis C virs core protein and the hosderived GOR protein," Clin. Exp. Immunol., 96(3):403-409 (1994).	

S:\DOCS\ESF\ESF-7636.DOC 031704

EXAMINER /Louise Humphrey/ DATE CONSIDERED 10/02/2007

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.